Thrombocytopenia

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Fostamatinib is a tyrosine kinase inhibitor.  TAVALISSE is formulated with the disodium hexahydrate salt of fostamatinib, a phosphate prodrug that converts to its pharmacologically active metabolite, R406, <span class="Italics">in vivo</span>.</p><p>The chemical name for fostamatinib disodium hexahydrate is disodium (6-[[5-fluoro-2-(3,4,5-trimethoxyanilino) pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate hexahydrate.  The molecular formula is C<span class="Sub">23</span>H<span class="Sub">24</span>FN<span class="Sub">6</span>Na<span class="Sub">2</span>O<span class="Sub">9</span>P∙6H<span class="Sub">2</span>O, and the molecular weight is 732.52. The structural formula is:</p><div class="Figure"><img alt="Chemical Structure" src="tavalisse-01.jpg"/></div><p>Fostamatinib disodium is a white to off-white powder that is practically insoluble in pH 1.2 aqueous buffer, slightly soluble in water, and soluble in methanol.</p><p>Each TAVALISSE oral tablet contains 100 mg or 150 mg fostamatinib, equivalent to 126.2 mg or 189.3 mg fostamatinib disodium hexahydrate, respectively.</p><p>The inactive ingredients in the tablet core are mannitol, sodium bicarbonate, sodium starch glycolate, povidone, and magnesium stearate. The inactive ingredients in the film coating are polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, iron oxide yellow, and iron oxide red.</p></section>

TAVALISSE

fostamatinib

fostamatinib 100 MG Oral Tablet

Tavalisse

fostamatinib 100 MG Oral Tablet [Tavalisse]

fostamatinib 150 MG Oral Tablet

fostamatinib 150 MG Oral Tablet [Tavalisse]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Formulary Information

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Tavalisse Rigel OneCare Enrollment Form 

Tavalisse Rigel OneCare Enrollment Form - Spanish

Enroll in Patient Savings Program 

Other HCP Resources 

About Tavalisse 

Side Effects 

Taking Tavalisse 

Tavalisse Together Support Program 

Patient Resources 

Patient Brochure 

Patient Brochure - Spanish

Patient Journal 

Patient Journal - Spanish 

Doctor Discussion Guide 

Instructions For Use: Chronic ITP